Anti-PD-1 monoclonal antibody combined CD3-retronectin activated T cell in heavy-treated renal cell cancer.
Lingdi Zhao(Zhengzhou University), Quanli Gao(Zhengzhou University), Yong Zhang(City University of Hong Kong), Yonghao Yang(Army Medical University), Wei Li(Wuhan University), Xiubao Ren(Tianjin Medical University Cancer Institute and Hospital)
Cited by 1
Related Papers
Abrogation of TGFβ Signaling in Mammary Carcinomas Recruits Gr-1+CD11b+ Myeloid Cells that Promote Metastasis
|Cancer Cell|2008|917
Gasdermin E–mediated target cell pyroptosis by CAR T cells triggers cytokine release syndrome
|Science Immunology|2020|555
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|508
Neutrophil-induced ferroptosis promotes tumor necrosis in glioblastoma progression
|Nature Communications|2020|409
IL-2 regulates tumor-reactive CD8+ T cell exhaustion by activating the aryl hydrocarbon receptor
|Nature Immunology|2021|374